Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pearland, TX
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pearland, TX
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Burlington, VT
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tarzana, CA
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tarzana, CA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Des Moines, IA
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Des Moines, IA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Covington, KY
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Covington, KY
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Metairie, LA
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Framingham, MA
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Framingham, MA
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
El Paso, TX
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
North Richland Hills, TX
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
North Richland Hills, TX
Click here to add this to my saved trials
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
Financial Incentives Augmented Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
Financial Incentives Augmented Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Deferoxamine for the Treatment of Hemochromatosis
Clinical Course of Patients With Transfusional Hemochromatosis on Deferoxamine
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Deferoxamine for the Treatment of Hemochromatosis
Clinical Course of Patients With Transfusional Hemochromatosis on Deferoxamine
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression
Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression
Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Sciences Center
mi
from
Denver, CO
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC (this site is only screening babies whose mother, father or full sibiling have type 1 diabetes)
mi
from
Pittsburgh, PA
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC (this site is only screening babies whose mother, father or full sibiling have type 1 diabetes)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Pacific Northwest Diabetes Research Institute
mi
from
Seattle, WA
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Pacific Northwest Diabetes Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Turku University Central Hospital
mi
from
Turku,
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Turku University Central Hospital
mi
from
Turku,
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Augusta University
mi
from
Gainesville, FL
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Augusta University
mi
from
Gainesville, FL
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Augusta University
mi
from
Atlanta, GA
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Augusta University
mi
from
Atlanta, GA
Click here to add this to my saved trials
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Augusta University
mi
from
Augusta, GA
TEDDY - The Environmental Determinants of Diabetes in the Young
Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community
Prospective Studies of Diabetes Mellitus and Its Complications in the Gila River Indian Community
Status: Enrolling
Updated:  12/31/1969
NIDDK, Phoenix
mi
from
Phoenix, AZ
Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community
Prospective Studies of Diabetes Mellitus and Its Complications in the Gila River Indian Community
Status: Enrolling
Updated: 12/31/1969
NIDDK, Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Family Management of Childhood Diabetes Study
Family Management of Childhood Diabetes Study
Status: Enrolling
Updated:  12/31/1969
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Family Management of Childhood Diabetes Study
Family Management of Childhood Diabetes Study
Status: Enrolling
Updated: 12/31/1969
Children's Memorial Hospital, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Family Management of Childhood Diabetes Study
Family Management of Childhood Diabetes Study
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Family Management of Childhood Diabetes Study
Family Management of Childhood Diabetes Study
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Family Management of Childhood Diabetes Study
Family Management of Childhood Diabetes Study
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Family Management of Childhood Diabetes Study
Family Management of Childhood Diabetes Study
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Detemir: Role in Type 1 Diabetes
Role of Insulin Aspart and Detemir to Assess Glucose Excursion in Children With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital Endocrine and Diabetes Clinic
mi
from
Houston, TX
Detemir: Role in Type 1 Diabetes
Role of Insulin Aspart and Detemir to Assess Glucose Excursion in Children With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital Endocrine and Diabetes Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Optimizing Adherence and Glycemia in Youth With New Insulin-dependent Diabetes Mellitus (IDDM)
Optimizing Adherence and Glycemia in Youth With New IDDM
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Optimizing Adherence and Glycemia in Youth With New Insulin-dependent Diabetes Mellitus (IDDM)
Optimizing Adherence and Glycemia in Youth With New IDDM
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Influence Of Endothelial Function On Central and Peripheral Causes Of Exercise Impairment In Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Influence Of Endothelial Function On Central and Peripheral Causes Of Exercise Impairment In Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Intensive Care Program for Youth With Diabetes
Intensive Care Program for Youth With Diabetes
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Intensive Care Program for Youth With Diabetes
Intensive Care Program for Youth With Diabetes
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Vascular Dysfunction in Diabetes: Genes and Hormones
Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hospital- 221 Longwood Avenue
mi
from
Boston, MA
Vascular Dysfunction in Diabetes: Genes and Hormones
Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital- 221 Longwood Avenue
mi
from
Boston, MA
Click here to add this to my saved trials
SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy
SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente of Northern California, Division of Research
mi
from
Oakland, CA
SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy
SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente of Northern California, Division of Research
mi
from
Oakland, CA
Click here to add this to my saved trials
Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention
Promoting Resilience in Youth With Type 1 Diabetes: Pilot of Strengths-Based Family Intervention to Improve Diabetes Outcomes (Diabetes Strengths Study)
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention
Promoting Resilience in Youth With Type 1 Diabetes: Pilot of Strengths-Based Family Intervention to Improve Diabetes Outcomes (Diabetes Strengths Study)
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes
The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes
The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Haleyville, AL
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Haleyville, AL
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tuscumbia, AL
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tuscumbia, AL
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Fountain Hills, AZ
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Fountain Hills, AZ
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Phoenix, AZ
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tempe, AZ
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tempe, AZ
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Harrisburg, AR
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Harrisburg, AR
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
North Little Rock, AR
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Searcy, AR
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Searcy, AR
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Alhambra, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Alhambra, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Carlsbad, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Coronado, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Coronado, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Costa Mesa, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Elk Grove, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Elk Grove, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Encinitas, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Hawaiian Gardens, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Hawaiian Gardens, CA
Click here to add this to my saved trials
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Huntington Beach, CA
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials